JP7626362B2 - 中枢神経系に神経保護ポリペプチドを送達する方法 - Google Patents

中枢神経系に神経保護ポリペプチドを送達する方法 Download PDF

Info

Publication number
JP7626362B2
JP7626362B2 JP2019521018A JP2019521018A JP7626362B2 JP 7626362 B2 JP7626362 B2 JP 7626362B2 JP 2019521018 A JP2019521018 A JP 2019521018A JP 2019521018 A JP2019521018 A JP 2019521018A JP 7626362 B2 JP7626362 B2 JP 7626362B2
Authority
JP
Japan
Prior art keywords
ala
gly
controlled release
exendin
neuroprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500163A (ja
JP2020500163A5 (enExample
Inventor
キム，ドン・ソク
キム，ヒ・ギュン
グレイグ，ナイジェル・エイチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JP2020500163A publication Critical patent/JP2020500163A/ja
Priority to JP2023016292A priority Critical patent/JP2023065401A/ja
Publication of JP2020500163A5 publication Critical patent/JP2020500163A5/ja
Application granted granted Critical
Publication of JP7626362B2 publication Critical patent/JP7626362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14212—Pumping with an aspiration and an expulsion action
    • A61M5/14228—Pumping with an aspiration and an expulsion action with linear peristaltic action, i.e. comprising at least three pressurising members or a helical member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019521018A 2016-10-20 2017-10-20 中枢神経系に神経保護ポリペプチドを送達する方法 Active JP7626362B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023016292A JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410748P 2016-10-20 2016-10-20
US62/410,748 2016-10-20
PCT/US2017/057606 WO2018075901A1 (en) 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016292A Division JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Publications (3)

Publication Number Publication Date
JP2020500163A JP2020500163A (ja) 2020-01-09
JP2020500163A5 JP2020500163A5 (enExample) 2024-11-28
JP7626362B2 true JP7626362B2 (ja) 2025-02-07

Family

ID=60382598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521018A Active JP7626362B2 (ja) 2016-10-20 2017-10-20 中枢神経系に神経保護ポリペプチドを送達する方法
JP2023016292A Pending JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016292A Pending JP2023065401A (ja) 2016-10-20 2023-02-06 中枢神経系に神経保護ポリペプチドを送達する方法

Country Status (12)

Country Link
US (2) US11273130B2 (enExample)
EP (2) EP3528836A1 (enExample)
JP (2) JP7626362B2 (enExample)
KR (2) KR102687778B1 (enExample)
CN (1) CN110191717A (enExample)
AU (1) AU2017345724B2 (enExample)
BR (1) BR112019008021A2 (enExample)
CA (1) CA3040906A1 (enExample)
MX (1) MX2019004476A (enExample)
SG (1) SG11201903462UA (enExample)
WO (1) WO2018075901A1 (enExample)
ZA (1) ZA201902486B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102687778B1 (ko) 2016-10-20 2024-07-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신경 보호 폴리펩티드를 중추 신경계에 전달하는 방법
CN114206374A (zh) * 2019-07-29 2022-03-18 佩特通公司 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物
MX2022001121A (es) 2019-07-29 2022-02-16 Peptron Inc Composicion farmaceutica para el tratamiento de la disquinesia inducida por levodopa o para la supresion de la progresion de la misma.
EP4153214A4 (en) 2020-05-22 2024-06-26 Trustees of Boston University Methods and compositions for treating a fibrotic disease
CN112014193B (zh) * 2020-07-24 2021-06-15 武汉大学中南医院 一种新的fj染色方法和装置
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116392576A (zh) * 2023-05-26 2023-07-07 南通大学 一种gip受体激动剂在制备治疗脊髓损伤修复靶点药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522743A (ja) 2007-03-27 2010-07-08 ペプトロン カンパニー リミテッド エキセンジン含有徐放性製剤組成物、エキセンジン含有徐放性微粒球、及びその製造方法
JP2014520159A (ja) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
EP1041968B1 (en) 1997-12-29 2004-03-03 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
ATE342051T1 (de) 1997-12-30 2006-11-15 Alza Corp Verabreichungssystem für wirkstoffe mit einem membranstöpsel
DE69906132T2 (de) 1998-12-31 2003-12-18 Alza Corp., Mountain View Osmotisches verabreichungsystem mit raumsparenden kolben
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
EP1411968B1 (en) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US9259432B1 (en) * 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
JP2015192425A (ja) 2014-03-28 2015-11-02 富士通株式会社 デマンド収容変更順序決定方法、およびデマンド収容変更順序決定プログラム
EP3132790A4 (en) * 2014-04-16 2017-11-22 Shandong Luye Pharmaceutical Co., Ltd. Exenatide-containing composition and preparation method therefor
KR102687778B1 (ko) 2016-10-20 2024-07-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신경 보호 폴리펩티드를 중추 신경계에 전달하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522743A (ja) 2007-03-27 2010-07-08 ペプトロン カンパニー リミテッド エキセンジン含有徐放性製剤組成物、エキセンジン含有徐放性微粒球、及びその製造方法
JP2014520159A (ja) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ａｌｚｈｅｉｍｅｒ’ｓ ＆ Ｄｅｍｅｎｔｉａ、２０１０年、Ｖｏｌ．１０、ｐ．Ｓ３８－Ｓ４６
Ｃｌｉｎｉｃａｌ Ｔｒｉａｌｓ，"Ｔｒｉａｌ ｏｆ Ｅｘｅｎａｔｉｄｅ ｆｏｒ Ｐａｒｋｉｎｓｏｎ’ｓ Ｄｉｓｅａｓｅ（ＥＸＥＮＡＴＩＤＥ－ＰＤ）"、［ｏｎｌｉｎｅ］、２０１５年３月１６日、［令和３年１０月１３日検索］、インターネット＜ＵＲＬ：ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏｒｙ／ＮＣＴ０１９７１２４２？Ａ＝６＆Ｂ＝６＆Ｃ＝ｍｅｒｇｅｄ＃ＳｔｕｄｙＰａｇｅＴｏｐ＞
ＰＥＰＴＲＯＮ，"ＳＲ－Ｅｘｅｎａｔｉｄｅ Ｆｏｒ ｔｈｅ Ｔｒｅａｔｍｅｎｔ ｏｆ Ｎｅｕｒｏｄｅｇｅｎｅｄａｔｉｖｅ Ｄｉｓｅａｓｅｓ"、［ｏｎｌｉｎｅ］、２０１４年５月、［令和３年１０月１３日検索］、インターネット＜ＵＲＬ：ｈｔｔｐ：／／ｐｅｐｔｒｏｎ．ｃｏｍ／ｍ／ｄｓ＿ｉｍｇｓ／ｓｕｂ０３／ＳＲ－Ｅｘｅｎａｔｉｄｅ＿ＮＤ＿Ｊｕｎｅ２０１４．ｐｄｆ＞
Ｔｈｅｒａｐｅｕｔｉｃ Ｒｅｓｅａｒｃｈ、２０１５年、Ｖｏｌ．３６、Ｎｏ．５、ｐ．４９７－５０２

Also Published As

Publication number Publication date
WO2018075901A9 (en) 2018-06-07
US20200046645A1 (en) 2020-02-13
US20220265563A1 (en) 2022-08-25
ZA201902486B (en) 2021-01-27
CN110191717A (zh) 2019-08-30
RU2019115110A (ru) 2020-11-24
JP2020500163A (ja) 2020-01-09
US11771657B2 (en) 2023-10-03
WO2018075901A1 (en) 2018-04-26
CA3040906A1 (en) 2018-04-26
EP4635569A2 (en) 2025-10-22
US11273130B2 (en) 2022-03-15
AU2017345724A1 (en) 2019-06-06
EP4635569A3 (en) 2025-12-31
WO2018075901A8 (en) 2019-05-23
RU2019115110A3 (enExample) 2021-03-02
KR20190086460A (ko) 2019-07-22
KR20210092335A (ko) 2021-07-23
BR112019008021A2 (pt) 2019-07-09
MX2019004476A (es) 2019-09-23
JP2023065401A (ja) 2023-05-12
EP3528836A1 (en) 2019-08-28
AU2017345724B2 (en) 2024-04-18
SG11201903462UA (en) 2019-05-30
KR102687778B1 (ko) 2024-07-23

Similar Documents

Publication Publication Date Title
US11771657B2 (en) Methods of delivering a neuroprotective polypeptide to the central nervous system
CA2846209C (en) Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
EP1861116B1 (en) Vegf antagonist formulations
JP2828250B2 (ja) 真性糖尿病の治療
US7531173B2 (en) Ophthalmic composition of a VEGF antagonist
US9919032B2 (en) Method for administering a sustained release formulation
CN102389413B (zh) 用于治疗糖尿病的组合物及其应用
RS53814B1 (sr) Eksendin za lečenje šećerne bolesti i smanjenje telesne težine
TW201410704A (zh) 長效胰島素及胰促泌素肽之液體製劑
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
JP2010514699A (ja) インスリン感受性および脂質プロファイルを改善するための長時間作用型ｇｌｐ−１受容体アゴニストの使用
US9463174B2 (en) Pharmaceutical composition for the treatment of type-1 diabetes
EP1838336A2 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
JP2017517561A (ja) 最適化ハムスターｒｅｇ３ガンマペプチドを利用する糖尿病を有する患者の間でのインスリン非依存性
RU2790566C2 (ru) Способы доставки нейропротективного полипептида в центральную нервную систему
EP3083672A1 (en) Pro-angiogenic peptides and peptide conjugates
US20230263860A1 (en) Methods And Compositions For Treating Stroke
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230213

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241118

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20241118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250114

R150 Certificate of patent or registration of utility model

Ref document number: 7626362

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150